The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Children’s Oncology Group (COG).
 
Rajen Mody
Consulting or Advisory Role - United Therapeutics
 
Arlene Naranjo
No Relationships to Disclose
 
Collin Van Ryn
No Relationships to Disclose
 
Alice L. Yu
Leadership - OPKO Health
Stock and Other Ownership Interests - OPKO Health
Honoraria - United Therapeutics
Consulting or Advisory Role - OBI Pharma
Travel, Accommodations, Expenses - United Therapeutics
 
Wendy B. London
Consulting or Advisory Role - United Therapeutics
 
Barry L. Shulkin
Consulting or Advisory Role - Navidea
 
Marguerite T Parisi
No Relationships to Disclose
 
Sabah-E-Noor Servaes
No Relationships to Disclose
 
Mitchell B Dicciani
No Relationships to Disclose
 
Paul M. Sondel
No Relationships to Disclose
 
John M. Maris
Research Funding - GlaxoSmithKline; Novartis
 
Julie R. Park
Travel, Accommodations, Expenses - Roche
 
Rochelle Bagatell
No Relationships to Disclose